Article · Wikipedia archive · Last revised Aug 8, 2026

LPH-48

LPH-48 is a selective serotonin 5-HT2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of alcoholism. Its route of administration has not been specified.

Last revised
Aug 8, 2026
Read time
≈ 2 min
Length
454 w
Citations
22
Source
Wikipedia ↗
LPH-48
Clinical data
Other namesLPH48
Routes of
administration		Unspecified1
Drug classSelective serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen12

LPH-48 is a selective serotonin 5-HT2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of alcoholism.123 Its route of administration has not been specified.1

The drug acts as a selective agonist of the serotonin 5-HT2A receptor.123 It is said to be an analogue of LPH-5 with similar characteristics but with faster metabolism and a shorter duration of action.3 LPH-5 is a highly selective serotonin 5-HT2A receptor agonist that is under development for major depressive disorder and has shown antidepressant-like effects in animals.456

LPH-48 is under development by Lophora.12 As of May 2024, it is in preclinical research for alcoholism.12 The chemical structure of LPH-48 does not yet seem to have been disclosed.1 However, Lophora has patented selective serotonin 5-HT2A receptor agonists for treatment of depression7 and the company is said to have patent protection for LPH-48.1 Additionally, the structure of its close analogue LPH-5 is known and this compound is a phenylpiperidine derivative.4

See also

See also

References

References

  1. "LPH 48". AdisInsight. 22 May 2024. Retrieved 30 October 2024. LPH 48 is a ligand therapeutic which has a similar pharmacological profile as psilocybin with superior selectivity and shorter duration, being developed by [...]
  2. "Delving into the Latest Updates on LPH-48 with Synapse". Synapse. 19 September 2024. Retrieved 30 October 2024.
  3. Lophora (31 May 2024). "Lophora Submits Clinical Trial Authorisation (CTA) Application to the French Medicines Agency (ANSM) for Lead CNS Drug LPH-5" (PDF). Retrieved 30 October 2024. About LPH-48: LPH-48 is a shorter acting direct analog of LPH-5 with similar optimized characteristics and safety profile, but with a shorter duration of action. LPH-48 is designed as a fast-follower that shows significantly faster metabolism, indicating a shorter duration of action in man. LPH-48 is a representative of the same proprietary compound class as LPH-5 and is therefore endowed with the same optimized characteristics including favorable drug-like properties and a safe pharmacological profile.
  4. M Ro Rsted E, Jensen AA, Smits G, Frydenvang K, Kristensen JL (May 2024). "Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists". Journal of Medicinal Chemistry. 67 (9): 7224–7244. doi:10.1021/acs.jmedchem.4c00082. PMC 11089506. PMID 38648420.
  5. "LPH 5". AdisInsight. 7 March 2023. Retrieved 30 October 2024.
  6. Jensen AA, Cecchi CR, Hibicke M, Bach AH, Kaadt E, Marcher-Rorsted E, et al. (22 April 2024). "The selective 5-HT2Areceptor agonist LPH-5 induces persistent and robust antidepressant-like effects in rodents". bioRxiv 10.1101/2024.04.19.590212.
  7. WO 2021/089824, Kristensen JL, Jensen AA, Märcher-Rørsted E, Leth-Petersen S, "5-HT2A agonists for use in treatment of depression", published 14 May 2021, assigned to Lophora ApS 
External links